1. Introduction {#sec1}
===============

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which started in the rectum and generally extended proximally in a continuous manner through part of, or the entire, colon \[[@B1]\]. The clinical course was unpredictable, marked by alternating periods of exacerbation and remission \[[@B2]\]. UC-associated colorectal cancer (CRC) represented a fraction of CRC cases, accounted for up to 5% of all CRC \[[@B3]\]. In contrast to sporadic CRC, UC-associated CRC did not follow the typical "adenoma-carcinoma" sequences \[[@B1]\]. Due to limited understanding of the natural history of UC-associated CRC, the knowledge concerning the CRC risk in UC patients was still inadequate.

The first retrospective analysis on the risk of CRC in UC was published in 1988. In this publication, the overall incidence of CRC in UC was reported as 4.25% \[[@B4]\]. Recent mounting evidences from numerous countries suggested that the CRC standardised incidence ratio (SIR) in UC may differ based on disease duration and geographic variation. For example, the 10-year cumulative probability of cancer after the diagnosis of UC was 4.9%, not having a higher risk of cancer than an age-and sex-matched general population \[[@B5]\]. However, there was no synthesis of risk factors associated with disease extent, disease duration, and geographic variation. Therefore, we did a systematic review and meta-analysis to investigate the risk of CRC in UC patients compared with disease extent, disease duration, and geographic variation.

2. Methods {#sec2}
==========

2.1. Search Strategy and Selection Criteria {#sec2.1}
-------------------------------------------

We did a comprehensive literature research according to the *Cochrane Handbook for Systematic Reviews of Interventions* and followed the PRISMA and MOOSE guidelines for the reporting of meta-analyses. We searched PubMed, scientific meetings, and the bibliographies of identified articles, with English language restrictions for studies published from 1988 to Dec. 2018. All relevant articles included UC-associated CRC patients. Medical subject heading or keywords used in the search included the following: "Ulcerative Colitis" or "Inflammatory Bowel Disease (IBD)" or "Colorectal Cancer" or "Colorectal Neoplasia". The full search strategies used for each database were described in [Figure 1](#fig1){ref-type="fig"}.

Articles were eligible for inclusion if they reported the UC patients were associated with CRC in terms of the sample size. We included incidence rates in our analyses as an indirect method of adjustment for disease extent, disease duration, and geography.

Two authors (Qing Zhou and Zhao-Feng Shen) independently screened the title and abstract according to these eligibility criteria, screened data extraction, and did quality evaluation. When the evaluation result was not consistent, they consulted other researchers to further resolve differences through consultation according to the literature on the raw data. When the title and abstract met the requirements of the literature, the full text was retrieved for data extraction. NoteExpress 2.0 was adopted to manage the literature, and the repeated literature was removed. The inclusion of the literature was checked according to the abovementioned inclusion criteria, and the related references were traced.

2.2. Exclusion Criteria {#sec2.2}
-----------------------

We excluded the studies in this meta-analysis that met the following inclusion criteria: The literature type did not belong to the category of UC-associated CRCThe literature type was a meta-analysis or summarizationThe literature type data was incomplete (UC and Crohn\'s disease could not be distinguished effectively) and the additional data could not be further obtainedThe literature type outcome evaluation index was not CRCThe literature type was Crohn\'s disease, CAP, family history of CRC, or colectomy for UCThe literature type was repeated or republished

2.3. Data Extraction {#sec2.3}
--------------------

Two researchers (Qing Zhou and Zhao-Feng Shen) independently extracted relevant information from all eligible studies using a predefined data extraction form: author, publication year, sample size, age, country, gender, disease extent, and disease duration. Diagnosis and confirmation of UC and CRC were according to the criteria \[[@B6]\]. For missing data, the researchers tried to contact the original literature author by e-mail to obtain relevant data. Data that cannot be obtained was converted according to the relevant requirements of the Cochrane evaluation manual (such as the calculation of standard deviation in continuous data).

2.4. Outcomes {#sec2.4}
-------------

The primary outcome measure was the incidence of CRC in UC patients, reported as SIR. We included SIR in our analyses as a direct method of adjustment. No restrictions about publication year, sample size, age, country, gender, disease extent, and disease duration were applied.

The secondary outcomes were measuring the incidence of CRC in UC patients from disease extent, disease duration, geographic variation, and literature reporting time.

2.5. Analysis {#sec2.5}
-------------

We used random-effects meta-analysis to assess the incidence of CRC in UC patients. To calculate the pooled SIR of CRC, we combined the extracted study-specific estimates and 95% CIs using the DerSimonian-Laird random-effects model.

Publication bias (small-study effects) was examined with visual assessment of the symmetry of a funnel plot, the asymmetry of which will be assessed through Begg-Mazumdar\'s rank test. Forest plots were made for the prevalence of the outcomes in overall and within groups.

Data manipulation and statistical analyses were undertaken using the R Software (version 3.4.4). All statistical tests, with the exception of the *Q* statistic, used a two-sided *α* value of 0.05 for significance.

The study was registered with PROSPERO, number [CRD42018102213](https://www.crd.york.ac.uk/prospero/).

2.6. Role of the Funding Source {#sec2.6}
-------------------------------

This study was supported by the Ministry of Science and Technology of the People\'s Republic of China (2017YFC1700602), the National Natural Science Foundation of China (Grant No. 81573978), and the State Clinical Research of TCM (JDZX2015086).

3. Results {#sec3}
==========

From 285 articles of potential relevance, 71 full-text articles were examined in detail and 58 studies were included in the final analysis; studies which identified 267566 UC patients, published from Nov. 1988 to Dec. 2018, with 2663 patients that reported UC-associated CRC were included in the meta-analysis. The population characteristics and outcomes of the included studies were summarized in [Table 1](#tab1){ref-type="table"}.

3.1. Overall Risk of CRC in UC Patients {#sec3.1}
---------------------------------------

The overall risk of CRC in UC patients among the 58 studies was 1.4% (95% CI: 1.2-1.6; [Figure 2](#fig2){ref-type="fig"}). Gender-specific risk estimate for CRC in UC was reported in 30 of the 58 studies and varied from 0.89 (95% CI: 0.56-1.43) to 1.05 (95% CI: 0.68-1.63) in women and men, which has no difference (*P* = 0.62). Disease extent-specific risk estimates for CRC in UC were reported in 21 of the 58 studies, which show that extensive UC and left-sided UC had a higher risk of CRC (SIR: 1.42, 95% CI: 0.83-2.42; SIR: 0.56, 95% CI: 0.38-0.83) than proctitis UC (SIR: 0.18, 95% CI: 0.01-0.03) (*P* \< 0.01) (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

3.2. Disease Duration Risk of CRC in UC Patients {#sec3.2}
------------------------------------------------

In the subgroup analysis by disease duration, the incidence of CRC in UC patients rose after 20 years of this disease duration ([Table 4](#tab4){ref-type="table"}).

3.3. Geographic Variation Risk of CRC in UC Patients {#sec3.3}
----------------------------------------------------

In the subgroup analysis by geographic variation, Oceania has a higher incidence than other continents; however, it has only one article (Tables [1](#tab1){ref-type="table"} and [5](#tab5){ref-type="table"}). In Europe, the risk of CRC in UC patients has no statistical difference in disease duration for 1-9 years, 10-20 years, 21-30 years, or more than 30 years. In Asia, the risk of CRC in UC increased after 10-20 years of this disease duration. In North America, the risk of CRC in UC increased significantly in more than 30 years of this disease duration (Tables [5](#tab5){ref-type="table"} and [6](#tab6){ref-type="table"}).

Furthermore, we analyzed the CRC incidence in UC patients in each country; we found that Japan, UK, and Austria have the highest incidence, while Canada and Korea have the lowest incidence ([Table 7](#tab7){ref-type="table"}).

3.4. The Literature Reporting Time of CRC Risk in UC Patients {#sec3.4}
-------------------------------------------------------------

In the subgroup analysis by literature reporting time, we found that the risk of CRC in UC patients was higher in 1988-1995. As the research progresses, the CRC risk in UC was stable and maintained between 1.1% and 1.6% ([Table 8](#tab8){ref-type="table"}).

4. Discussion {#sec4}
=============

UC, an uncontrolled colorectal inflammation, associated with systemic immune dysregulation, which impaired tumor surveillance, might play a role in colorectal carcinogenesis. Unlike the "adenoma-carcinoma sequence" classically described in sporadic CRC, UC-associated CRC arose from a larger field of colorectal mucosa that was "preconditioned" with a mutational burden that conferred an increased propensity for further dysplasia progression, a phenomenon known as "field cancerization" \[[@B55]\], which followed a sequence of genetic alterations "inflammation-dysplasia-carcinoma" \[[@B63]\]. Chronic colorectal inflammation generated extensive damage to epithelial cells that led to increased cell replication and/or direct DNA damage \[[@B1]\], which was known as one risk factor for the occurrence of CRC in UC patients \[[@B28]\].

This study first provided a picture of the incidence rate of UC-associated CRC from disease extent, disease duration, and geographic variation. Results showed that the overall risk of UC-associated CRC was 1.4%, which increased with disease duration. Extensive UC and left-sided UC had a greater risk of CRC than proctitis UC. There was no obvious gender specificity in CRC risk in UC patients. The strength of this study lies in the fact that we chose to focus on the CRC risk in UC patients from geographic variation. Results showed that the Asian and North American UC patients seemed to have a higher CRC risk. The time of malignant transformation in Asian UC patients started after 10-20 years of this disease duration. North American UC-associated CRC patients significantly increased in more than 30 years of this disease duration.

In this study, we can find that UC patient-relevant endpoint, the risk of CRC, has not decreased over the past decade, and the overall CRC incidence was stable from 1996 until today, which stayed around 1.1% to 1.6%. So the management of UC is still complex, and significant gaps in the literature remained regarding how clinicians could identify the risk associated with CRC and enhance the prevention of UC-associated CRC. 5-Aminosalicylate medications (mesalamine or sulfasalazine), the foundational first-line therapy for the induction and maintenance of mild-to-moderate UC, seemed not to protect against the likelihood of carcinogenesis at doses greater than 2.4 grams daily and still needed to be proven \[[@B64]\]. Other medicines, such as thiopurines, reduced the immunosurveillance of malignant cells and impaired control of oncogenic viruses \[[@B65]\]. Prolonged treatment with thiopurines has been shown to determine an increased risk of a broad range of cancers in UC patients \[[@B66]\]. The impact of UC-related drug therapy on CRC development remained a matter of debate, and the potential benefit of surgery should need to be placed in the context of the risks associated with undertaking complex abdominopelvic reconstructive surgery. Therefore, UC-associated CRC rates still remained a challenging problem for UC patients.

At present, the majority of CRC cases (70%) could be explained by an inadequate surveillance procedure before the CRC diagnosis, and CRC is responsible for approximately 15% of deaths due to UC \[[@B67]\]. Therefore, it is not surprising that researchers have focused efforts on surveillance screening as an adjunct therapy to UC patients for CRC occurrence. UC patients need to be accurately evaluated for the risk of CRC according to the disease extent, disease duration, and geography and need to adhere to a surveillance schedule, such as screening colonoscopy, which should be performed every 1 to 3 years, because the malignant changes and the surrounding inflammation often grow flat and multifocal \[[@B68]\].

5. Conclusion {#sec5}
=============

In a systematic review of the literature, we found that the incidence of CRC in UC patients increased with the disease duration. Asian and North American UC patients were more prone to concomitant CRC.

6. Limitations {#sec6}
==============

Our study has limitations. Patients with Crohn\'s disease, CAP, and a family history of CRC and who have undergone colectomy for UC were not included in this study. Patients with UC associated with extracolorectal malignancies (small intestine, blood systems, lung, thyroid, hepatobiliary, skin, melanoma, urinary bladder, breast, genital tract, and so on) were not included, which greatly reduced the risk of cancer in UC. Moreover, our search had English language restrictions. Articles in languages other than English were not included.

UC:

:   Ulcerative colitis
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:   Standardised incidence ratio
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:   Colorectal adenomatous polyp.
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###### 

Population and study characteristics.

  Author                              Sample size (UC)   Study period   Mean age at diagnosis (UC)   Country          Sample size (CRC)   Mean age at diagnosis (CRC)   Gender   Disease extent   Time of duration (year)             
  ----------------------------------- ------------------ -------------- ---------------------------- ---------------- ------------------- ----------------------------- -------- ---------------- ------------------------- ---- ---- ---------
  Hata et al. \[[@B7]\]               217                1979-2001      31.4                         Japan            5                   46.6                          0        0                4                         1    0    15.2
  Kim et al. \[[@B8]\]                7061               1970-2005      37.9                         Korea            26                  49.6                          8        18               0                         0    0    12.7
  Gong et al. \[[@B9]\]               3922               1998-2009      40                           China            34                  57.5                          14       20               10                        12   12   12.8
  Matsuoka et al. \[[@B10]\]          1274               1984-2010      30                           Japan            83                  52                            43       40               66                        17   10   22
  Zhang et al. \[[@B11]\]             624                2000-2012      39                           China            4                   54.5                          2        2                4                         0    0    15.5
  Lee et al. \[[@B12]\]               2798               1989-2013      33                           Korea            18                  48                            7        11               16                        2    0    15
  Choi et al. \[[@B13]\]              522                2003-2013      0                            Korea            12                  0                             0        0                0                         0    0    0
  Shi et al. \[[@B14]\]               1225               1981-2013      41                           China            15                  0                             0        0                0                         0    0    0
  Yoshino et al. \[[@B15]\]           2137               2003-2013      0                            Japan            43                  53                            28       15               34                        8    1    13
  Wang et al. \[[@B16]\]              2663               1998-2013      43.1                         China            18                  0                             0        0                0                         0    0    19.27
  Jung et al. \[[@B17]\]              9785               2011-2014      0                            Korea            31                  0                             20       11               0                         0    0    0
  Kishikawa et al. \[[@B18]\]         289                1979-2014      33                           Japan            9                   49                            5        4                28                        5    0    16
  Bopanna et al. \[[@B19]\]           1012               2004-2015      32.1                         India            20                  53.25                         14       6                16                        4    0    18.7
  Selinger et al. \[[@B20]\]          504                1977-1992      0                            Australia        24                  0                             0        0                12                        8    4    0
  Gupta et al. \[[@B21]\]             418                1996-1997      26.8                         USA              1                   0                             0        0                0                         0    0    0
  Jess et al. \[[@B22]\]              378                1940-2001      34                           USA              6                   50.67                         4        2                4                         2    0    13.67
  Bitton et al. \[[@B23]\]            15346              1999-2008      0                            Canada           53                  0                             37       16               0                         0    0    0
  Hou et al. \[[@B24]\]               20949              1998-2009      0                            USA              168                 67                            97       71               0                         0    0    3.6
  Ananthakrishnan et al. \[[@B25]\]   5569               1998-2010      0                            USA              126                 0                             0        0                0                         0    0    0
  Navaneethan et al. \[[@B26]\]       997                1998-2011      0                            USA              2                   0                             0        0                0                         0    0    0
  Yadav et al. \[[@B5]\]              462                1940-2011      35                           USA              13                  66                            6        7                0                         0    0    31
  Ananthakrishnan et al. \[[@B27]\]   3546               2010-2013      0                            USA              83                  0                             0        0                0                         0    0    0
  Sonnenberg and Genta \[[@B28]\]     37043              2008-2014      49.6                         USA              54                  0                             0        0                0                         0    0    0
  Hou et al. \[[@B29]\]               881                1999-2014      0                            USA              21                  0                             0        0                0                         0    0    0
  Bettner et al. \[[@B30]\]           75                 1990-2015      29                           USA              1                   59                            0        0                0                         0    0    11.1
  Gyde et al. \[[@B4]\]               823                1944-1976      33.66                        UK/Sweden        35                  56.69                         13       22               28                        7    0    23.03
  Moody et al. \[[@B31]\]             175                1972-1981      58.4                         UK               10                  67                            6        4                7                         3    0    9.6
  Ekbom et al. \[[@B32]\]             3117               1922-1983      0                            Sweden           91                  0                             52       39               35                        17   9    0
  Lennard-Jones et al. \[[@B33]\]     401                1966-1987      29.73                        UK               22                  50.05                         13       9                0                         0    0    20.31
  Löfberg et al. \[[@B34]\]           72                 1973-1988      0                            Sweden           1                   42.25                         0        0                0                         0    0    0
  Stewtnius et al. \[[@B35]\]         471                1958-1990      38.3                         Sweden           9                   49.88                         3        6                7                         1    1    12.22
  Biasco et al. \[[@B36]\]            65                 1980-1992      32.9                         Italy            4                   59.5                          0        0                0                         0    0    13
  Wandall et al. \[[@B37]\]           801                1973-1993      41                           Denmark          6                   57.33                         4        2                4                         1    1    10.83
  Palli et al. \[[@B38]\]             689                1978-1996      0                            Italy            4                   0                             0        0                0                         0    0    0
  Winther et al. \[[@B39]\]           1160               1962-1997      0                            Denmark          8                   0                             6        2                0                         0    0    0
  Viscido et al. \[[@B40]\]           2006               1964-1997      38.5                         Italy            28                  0                             0        0                0                         0    0    0
  Goldacre et al. \[[@B41]\]          6990               1963-1999      0                            UK               103                 0                             0        0                0                         0    0    0
  Lindberg et al. \[[@B42]\]          90                 1977-2002      0                            Sweden           8                   0                             0        0                0                         0    0    0
  Jess et al. \[[@B43]\]              1437               1978-2002      0                            Denmark          15                  0                             0        0                0                         0    0    0
  Hemminki et al. \[[@B44]\]          27606              1964-2004      0                            Germany/Sweden   482                 0                             0        0                0                         0    0    0
  Katsanos et al. \[[@B45]\]          182                1983-2004      51.2                         Greece           3                   0                             2        1                0                         0    0    0
  Katsanos et al. \[[@B46]\]          776                1991-2004      0                            Netherlands      7                   61.3                          0        0                0                         0    0    5.4
  Jess et al. \[[@B47]\]              1575               1962-2005      0                            Denmark          14                  0                             8        6                0                         0    0    0
  Stolwijk et al. \[[@B48]\]          293                1980-2005      33.8                         Netherlands      23                  49.2                          14       9                22                        1    0    10.2
  Lakatos et al. \[[@B49]\]           723                2002-2005      36                           Hungary          13                  51                            0        0                8                         5    0    19
  Cheddani et al. \[[@B50]\]          474                1998-2006      69                           France           8                   75                            0        0                0                         0    0    7.4
  Manninen et al. \[[@B51]\]          1254               1986-2007      34                           Finland          16                  47.69                         14       2                10                        6    0    16.1875
  Jess et al. \[[@B52]\]              32911              1979-2008      44.9                         Denmark          268                 64                            132      136              0                         0    0    19.1
  Gordillo et al. \[[@B53]\]          403                2006-2009      42.91                        Spain            3                   58.9                          3        0                2                         1    0    12.5
  Kappelman et al. \[[@B54]\]         35152              1978-2010      46.5                         Denmark          437                 0                             0        0                0                         0    0    7.8
  Choi et al. \[[@B55]\]              1375               2003-2012      30                           UK               88                  55.5                          54       34               0                         0    0    25.5
  Choi et al. \[[@B56]\]              987                2003-2012      30                           UK               14                  0                             0        0                0                         0    0    0
  Hovde et al. \[[@B57]\]             519                1990-2013      0                            Norway           14                  0                             10       4                0                         0    0    0
  Van den Heuvel et al. \[[@B58]\]    1644               1991-2013      45                           Netherlands      12                  62.75                         6        6                4                         7    1    3.42
  Nowacki et al. \[[@B59]\]           434                2013-2013      45.7                         Germany          10                  54.7                          5        5                6                         4    0    12
  Rutegård et al. \[[@B60]\]          323                1977-2014      0                            Sweden           10                  0                             0        0                0                         0    0    0
  Biancone et al. \[[@B61]\]          22666              2012-2014      0                            Italy            24                  64                            0        0                0                         0    0    12
  Kekilli et al. \[[@B62]\]           275                1994-2008      35.9                         Turkey           3                   0                             0        0                0                         0    0    0

###### 

Gender-specific risk of CRC in UC patients.

  Gender   Proportion   95% CI
  -------- ------------ ---------------
  Men      0.0105       0.0068-0.0163
  Women    0.0089       0.0056-0.0143

▲*P* \< 0.05 vs. women; ▲▲*P* \< 0.01 vs. women.

###### 

Disease extent risk of CRC in UC patients.

  Extent       Proportion   95% CI
  ------------ ------------ ---------------
  Extensive    0.0142▲▲     0.0083-0.0242
  Left-sided   0.0056▲▲     0.0038-0.0083
  Proctitis    0.0018       0.0010-0.0031

▲*P* \< 0.05 vs. proctitis; ▲▲*P* \< 0.01 vs. proctitis.

###### 

Disease duration risk of CRC in UC patients.

  Follow-up            Article (*n*)   Proportion   95% CI        Weight (random)
  -------------------- --------------- ------------ ------------- -----------------
  1-9 years            11              0.007        0.005-0.009   22.40%
  10-20 years          22              0.013        0.010-0.016   36.60%
  21-30 years          11              0.02▲        0.014-0.026   15.60%
  More than 30 years   14              0.017▲       0.013-0.022   25.40%

▲*P* \< 0.05 vs. 1-9 years; ▲▲*P* \< 0.01 vs. 1-9 years.

###### 

Geographic variation risk of CRC in UC patients.

  Area            Article (*n*)   Proportion   95% CI        Weight (random)
  --------------- --------------- ------------ ------------- -----------------
  Asia            13              0.013        0.009-0.017   24.90%
  North America   11              0.011        0.007-0.014   22.20%
  Europe          33              0.017        0.014-0.020   52.20%
  Oceania         1               0.048▲       0.029-0.066   0.70%

▲*P* \< 0.05 vs. Europe; ▲▲*P* \< 0.01 vs. Europe.

###### 

Geographic variation in UC patients in different disease durations.

  --------------------------------------------------------------------------------------------------------------------------------------
  Area            1-9 years                    10-20 years                   21-30 years                   More than 30 years
  --------------- ---------------------------- ----------------------------- ----------------------------- -----------------------------
  Asia            0.0032\                      0.0128\                       0.0188\                       0.0106\
                  \[0.0022; 0.0045\] *n* = 1   \[0.0081; 0.0201\]▲ *n* = 6   \[0.0051; 0.0671\]▲ *n* = 4   \[0.0013; 0.0819\]▲ *n* = 2

  North America   0.0043\                      0.0120\                       ---                           0.0228\
                  \[0.0009; 0.0196\] *n* = 4   \[0.0058; 0.0245\] *n* = 5                                  \[0.0132; 0.0390\]▲ *n* = 2

  Europe          0.0097\                      0.0141\                       0.0222\                       0.0193\
                  \[0.0020; 0.0461\] *n* = 6   \[0.0089; 0.0221\] *n* = 10   \[0.0104; 0.0465\] *n* = 7    \[0.0144; 0.0257\] *n* = 10

  Oceania         ---                          0.048\                        ---                           ---
                                               \[0.029; 0.066\] *n* = 1                                    
  --------------------------------------------------------------------------------------------------------------------------------------

▲*P* \< 0.05 vs. 1-9 years; ▲▲*P* \< 0.01 vs. 1-9 years.

###### 

CRC incidence in UC patients by country.

  Nation        Article (*n*)   Proportion   95% CI        Weight (random)
  ------------- --------------- ------------ ------------- -----------------
  Canada        1               0.003        0.003-0.004   2.80%
  Korea         4               0.005        0.002-0.007   9.30%
  Spain         11              0.007        0.000-0.016   1.70%
  China         4               0.008        0.006-0.010   9.40%
  Italy         4               0.008        0.000-0.016   7.40%
  Denmark       6               0.009        0.007-0.012   14.70%
  Turkey        1               0.011        0.000-0.023   1.20%
  Finland       1               0.013        0.007-0.019   2.10%
  USA           10              0.013        0.008-0.017   19.40%
  Greece        1               0.016        0.000-0.035   0.70%
  France        1               0.017        0.005-0.028   1.30%
  Germany       2               0.018        0.016-0.019   3.80%
  Hungary       1               0.018        0.008-0.028   1.50%
  Netherlands   3               0.019        0.004-0.035   4.80%
  India         1               0.02         0.011-0.028   1.70%
  Norway        1               0.027        0.013-0.041   1%
  Sweden        5               0.027        0.017-0.036   4.50%
  Japan         4               0.035        0.012-0.058   4.50%
  UK            6               0.039        0.022-0.055   7.50%
  Austria       1               0.048        0.029-0.066   0.70%

###### 

The literature reporting time in CRC risk in UC patients.

  Reporting time   Article (*n*)   Proportion   95% CI        Weight (random)
  ---------------- --------------- ------------ ------------- -----------------
  1988-1995        6               0.033        0.022-0.043   5.40%
  1996-2000        3               0.011        0.000-0.021   4.60%
  2001-2005        5               0.014        0.006-0.023   6%
  2006-2010        9               0.011        0.005-0.016   6%
  2011-2015        17              0.016        0.013-0.020   6%
  2016-today       18              0.012        0.009-0.015   6%
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